Challenges With Current Treatment Options for CSU

Author(s):

Key Takeaways

Biologics for CSU face challenges including high costs, side effects, and the necessity for accurate patient selection to ensure treatment efficacy.
BTK is a key player in mast cell degranulation, making it an ideal target for CSU treatment by potentially reducing histamine release.
Targeting BTK offers a more specific treatment approach for CSU, addressing the condition's underlying pathophysiology.

Panelists discuss the challenges associated with using biologics for chronic spontaneous urticaria (CSU), including issues related to accessibility and cost, while also explaining why Burton tyrosine kinase (BTK) is considered an ideal target for CSU treatment due to its role in mediating mast cell degranulation.

EP: 1.Overview of CSU: Prevalence and Presentations

EP: 2.Impact of CSU on Patient Quality of Life

EP: 3.Pathophysiology of CSU and Role of BTK

EP: 4.Diagnostic Approach to CSU

EP: 5.Role of Testing in CSU Diagnosis

EP: 6.Referring CSU Patients to a Specialist

EP: 7.Treatment Goals and Guidelines for CSU

EP: 8.Role of Antihistamines, Steroids and Biologics in Treating CSU

Now Viewing

EP: 9.Challenges With Current Treatment Options for CSU

EP: 10.Future Landscape of BTK Inhibitors for CSU

EP: 11.Patient Education Tips for CSU and Final Thoughts

Video content above is prompted by the following:

What are the challenges associated with the use of biologics for CSU?
We previously discussed the role that BTK plays in mediating mast cell degranulation. Why does this make BTK an ideal target for CSU treatment?